Background-Platelet-derived nitric oxide inhibits platelet aggregation via constitutive NO synthase (NOS). Tetrahydrobiopterin (BH 4 ), a cofactor of NOS, augments NO formation, whereas its deficiency decreases NO bioactivity and increases superoxide generation by NOS. The roles of intraplatelet BH 4 in platelet aggregation and thrombus formation, however, are unknown. Accordingly, we investigated whether intraplatelet BH 4 is involved in regulating cyclic flow variations (CFVs) and platelet aggregation in a canine model with stenosed and endothelium-injured coronary arteries that mimics acute coronary syndromes in humans. Methods and Results-After developing CFVs, dogs received saline or BH 4 (10 or 30 mg/kg) intravenously. Intraplatelet BH 4 and cGMP levels were decreased and intraplatelet nitrotyrosine production was increased during CFVs. ADP-and U46619-induced ex vivo platelet aggregation and platelet P-selectin expression were augmented during CFVs. BH 4 administration restored intraplatelet BH 4 and cGMP levels and decreased intraplatelet nitrotyrosine production, resulting in reduced CFVs and inhibited ex vivo platelet aggregation and platelet P-selectin expression. CFVs again developed after N G -monomethyl-L-arginine, an inhibitor of NOS, in BH 4 -treated dogs. Ex vivo platelet NOS activity at baseline, during CFVs, and after BH 4 administration did not differ.
Conclusions-Intraplatelet